Status:

RECRUITING

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Lead Sponsor:

Hebei Medical University Fourth Hospital

Conditions:

Lung Adenocarcinoma

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with p...

Eligibility Criteria

Inclusion

  • Patients with metastatic (stage IV) lung adenocarcinoma who have not been systematically treated and are histologically or cytologically confirmed as unable to undergo radical surgery or radiotherapy based on AJCC Stage VIII;
  • Patients with brain metastases confirmed by imaging;
  • Patients with asymptomatic BMS after initial diagnosis, local BMS surgery or radiotherapy;
  • ECOG PS: 0-1;
  • Measurable target lesions outside the skull (as per RECIST 1.1);
  • Life expectancy greater than 3 months;

Exclusion

  • Patients had been treated with immune checkpoint inhibitors such as anti-PD-1, PD-L1, or CTLA-4 therapy;
  • The patient had received systemic chemotherapy as advanced treatment;
  • Patients with EGFR mutation or ALK gene translocation;
  • The patient had received approved systemic anticancer therapy or systemic immunomodulators (including but not limited to interferon, interleukin 2, and tumor necrosis factor) within 4 weeks prior to initial administration;
  • Clinically uncontrolled pleural fluid or ascites requiring puncture drainage within 2 weeks prior to initial administration;

Key Trial Info

Start Date :

May 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 12 2026

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT06056115

Start Date

May 1 2023

End Date

December 12 2026

Last Update

September 28 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital)

Shijiazhuang, Hebei, China